US Medicare launches GLP-1 Bridge program for weight‑loss drugs

The U.S. Centers for Medicare & Medicaid Services has begun a temporary federal pilot, the Medicare GLP‑1 Bridge, allowing qualifying Medicare beneficiaries to obtain weight‑loss medications at about $50 a month. Eligible adults must be enrolled in Medicare Part D, be 18 years or older, and meet BMI criteria (≥35, or 27‑34.9 with obesity‑related health complications). The program, running through December 2027, covers semaglutide (Wegovy), tirzepide (Zepbound) and the experimental oral agent orforglipron (Foundayo).

An illustrative case is 69‑year‑old Barbara Senich, who reduced her weight from a peak of 340 lb to about 137 lb using a combination of Zepbound, metformin and Contrave. She says, “This is the thing that’s been the miracle for me, is the maintenance.” Senich’s experience highlights both the clinical benefit and the financial strain, as she has had to pay out‑of‑pocket despite a LillyDirect assistance program. Experts caution that affordability should not be the sole driver; geriatrician Dr. John Batsis notes, “Just because you can doesn’t mean you should.”

Analyses by the health‑policy nonprofit KFF estimate that roughly 3.8 million Americans would qualify for the bridge based on 2023 data. By reducing drug costs, the program aims to improve health outcomes for seniors and potentially lower long‑term Medicare spending linked to obesity‑related conditions such as heart disease, diabetes, cancer, dementia and arthritis.